IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device.

NCT ID: NCT04409808

Last Updated: 2022-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-21

Study Completion Date

2022-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To perform a safety study on the prototype IRIS vitrectomy device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

to determine the safety and effectiveness of the device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitrectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IRIS vitrectomy device

all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device

Group Type EXPERIMENTAL

IRIS

Intervention Type DEVICE

prototype IRIS vitrectomy device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IRIS

prototype IRIS vitrectomy device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients that are scheduled for vitrectomy surgery, regardless of the indication
* Both vitrectomy-only and combined phaco-vitrectomy surgeries
* Primary or repeat vitrectomy
* General or local anesthesia, or combination
* All ages
* Informed consent (from parents in patients \<18 years old)

Exclusion Criteria

* Unable to obtain informed consent from patient (or from parents in children)
* No post-operative 8 week visit is anticipated
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Stalmans, PHd MD

Role: PRINCIPAL_INVESTIGATOR

Universitaire Ziekenhuizen KU Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven

Leuven, Vlaams Brabant, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S62660

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cataract Refractive Suite Study
NCT02974140 TERMINATED NA